Laurus Labs Limited is a research-driven pharmaceutical and biotechnology company founded in 2005, having established a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs, cardiovascular, and gastro therapeutics. The company also offers integrated CMO and CDMO services to global innovators from clinical phase drug development to commercial manufacturing.
The company employs over 6,500 people, including around 1,050 scientists, across more than 11 facilities that are approved by global agencies including USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, and TGA. Originally incorporated as Laurus Labs Private Limited on September 19, 2005, in Hyderabad, Andhra Pradesh, the company was subsequently converted into a public limited company on February 12, 2007.
Laurus Labs operates through three primary business segments that drive its revenue growth. The Laurus Generics segment focuses on the development, manufacturing, and sale of APIs and advanced intermediates, along with oral solid formulations and finished dosage forms (FDFs). The Laurus Synthesis segment specializes in key starting materials (KSM), intermediates and APIs, particularly for new chemical entities (NCEs).
The Generic API segment contributed 46% of revenue in 9M FY25 compared to 41% in FY22, with the company having one of the largest high-potent API manufacturing capacities in India and being the world's leading third-party supplier of antiretroviral APIs. The company collaborates with the top 10 global generic pharmaceutical companies, distributing its APIs across 56 countries, with primary focus on developing anti-retroviral, Hepatitis C and oncology drugs.
Laurus Labs operates over 55 state-of-the-art R&D labs strategically positioned in India and the US, manufacturing over 90 APIs across ten cutting-edge manufacturing facilities with more than 7 million litres of reactor capacity. The company has API manufacturing facilities in Visakhapatnam, an FDF drug manufacturing facility in Achutapuram, and a research and development centre at IKP Knowledge Park in Hyderabad, which is approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology of India.
With a total of 322 filed patents, the company currently owns 203 patents. Over its operational tenure, Laurus Labs has successfully brought more than 60 products to market across its three business segments. The company reported research and development spending of ₹66 crore in Q4 FY25, representing 3.7% of revenue.
Laurus Labs has a market capitalisation of ₹37,839 crore as of June 2025. The company delivered strong financial performance in FY25, demonstrating significant growth across key metrics.
Revenue stood at ₹5,554 crore for FY25, representing 10% growth, while EBITDA reached ₹1,115 crore with 40% growth. The EBITDA margin improved substantially to 20.1%, supported by continuing operating leverage within the CDMO business.
For the full year, net profit rose 123.18% to ₹358.32 crore in FY25 compared to ₹160.55 crore in FY24, while sales increased 10.18% to ₹5,553.96 crore from ₹5,040.83 crore in the previous year.
Revenue from operations jumped 19.49% year-over-year to ₹1,720.30 crore in Q4 FY25, while profit before tax soared 191.17% to ₹312.34 crore during the quarter ended March 31, 2025. EBITDA stood at ₹477 crore in Q4 FY25, recording growth of 84% compared to ₹259 crore in Q4 FY24.
Revenue from the CDMO segment jumped 85% to ₹490 crore in Q4 FY25, with revenue from small molecules increasing 95% year-over-year to ₹461 crore, driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets.
The company has made strategic investments in renewable energy, enabling access to 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. This investment aims to reduce electricity costs, ensure reliable green power supply, and obtain carbon credits, contributing to the company's environmental, social, and governance objectives.
In June 2025, Laurus Labs invested ₹39.99 crore in Laurus Bio via preferential allotment of 15,414 CCPS. CARE reaffirmed Laurus Labs' ratings in July 2025, with long-term CARE AA stable outlook revised from negative.
The company's board approved a second interim dividend of ₹0.80 per share of ₹2 each for FY25, with May 9, 2025 fixed as the record date and payment scheduled on or after May 20, 2025. Promoter holding in Laurus Labs has increased to 27.62% as of March 2025 from 27.18% as of June 2024.
Looking ahead, the company remains confident in its growth expectations as it focuses on executing long-lead programs, ramping up new assets with revenue increasing over FY25 while maintaining focus on operational excellence. The capital allocation strategy remains unchanged, prioritizing investments into high-value business opportunities.
